In vitro studies showed that Cltx binds to glioma cells without affecting normal cells; Cltx can bind endogenously to MMP-2 expressed in glioma cells, thus generating a loss of the gelatinase activity of the glioma and decreasing the expression of MMP2. This evidence concerns the gene MMP2 and central nervous system cancer.